Apollo Therapeutics, a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, today announces the close of $226.5 million in a Series C financing led by lead investor Patient Square Capital. Source: BIA News 6/9/2023